Aurobindo Pharma Ltd.

SECTOR: Pharmaceuticals & Drugs

759.15
₹ 8.5 (1.13%)
Today's High: 791 Today's Low : 754.25
52 Week High: 758.65 52 Week Low : 281.15
 FinStar
FinStar Indicates the overall health and quality of a stock based on Finology Research.
Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

 Company Essentials

Market Cap

44481.529502235 Cr.

P/E

27.67

P/B

3.56

Face Value

₹1

Div. Yield

0.34%

Book Value (TTM)

213.2256

Enterprise Value

48925.559502235 Cr.

CASH

75.77 Cr.

DEBT

4519.8 Cr.

Promoter Holding

52.01%

EPS (TTM)

27.4404

Sales Growth

19.36 %

ROE

14.34 %

ROCE

14.85 %

Profit Growth

-15.61 %

No. of Shares

58.5938609 Cr.

Add your own Ratio
* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

 Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

 Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

 Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Sales Growth

1 Year19.36%
3 Year10.17%
5 Year11.51%

 Profit Growth

1 Year-15.62%
3 Year-2.03%
5 Year5.47%

 ROE

1 Year14.34%
3 Year18.78%
5 Year23.06%

 ROCE

1 Year14.85%
3 Year17.87%
5 Year20.88%

 Debt Equity

0.4

 Price to Cash Flow

84.45

  Interest Cover Ratio

9.51

 CFO/PAT (5 Yr Avg.)

0.682146160352797

 Share Holding Pattern

 Promoter Pledging %

Date Promoter % Pledge %
Mar 2020 52.01 6.17
Dec 2019 51.87 4.99
Sep 2019 51.87 4.2
Jun 2019 51.87 3.82
Mar 2019 51.87 3.49
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 9.51.
  • The Company has been maintaining an effective average operating margins of 24.686% in the last 5 years.
  • Company’s PEG ratio is -1.77228783091776.

 Limitations

  • The company has shown a poor profit growth of -2.02853550568921% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.1731030692745% for the Past 3 years.
  • Promoter pledging has increased from 4.99% to 6.17% in 1 quarter.

 Quarterly Result (All Figures are in Crores.)

Particulars Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019
Net Sales 3248.1 3280.58 3078.83 3221.66 3345.67
Other Income 136.87 28.31 30.14 33.64 37.98
Total Expenditure 2649.78 2546.24 2528.42 2590.45 2694.49
Operating Profit 735.19 762.65 580.55 664.85 689.16
Interest 41.41 34.84 31.95 24.86 21.31
Depreciation 109.1 109.33 115.15 117.93 118.55
Exceptional Items 0 0 0 0 0
Profit Before Tax 584.68 618.48 433.45 522.06 549.3
Tax 121.17 158.34 102.95 123.93 130.23
Profit After Tax 463.51 460.14 330.5 398.13 419.07

 Profit & Loss (All Figures are in Crores except Adjusted EPS in Rs.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Net Sales 8095.1 9166.2 9607.1 10269.9 12257.9
Other Income 67.2 188.4 136 80.7 199.2
Total Expenditure 5844.7 6714.4 7233.1 7599.9 9848.6
Operating Profit 2317.6 2640.2 2509.9 2750.7 2608.5
Interest 132.1 229.3 45.2 52.9 230.9
Depreciation 245.2 263 286.2 354.8 413
Exceptional Items 0 0 0 0 0
Profit Before Tax 1940.4 2147.8 2178.6 2342.9 1964.6
Tax 424 521.1 471.8 530.2 434.9
Net Profit 1516.4 1626.7 1706.8 1812.8 1529.7
Adjusted EPS 26 28 29 31 26

 Balance Sheet (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Equity and Liabilities
Share Capital 29.2 58.52 58.59 58.59 58.59
Total Reserves 5330.34 6807.33 8377.59 9923.99 11292.03
Borrowings 687.16 334.76 118.9 0 0
Other N/C liabilities 232.99 14.4 20.79 57.08 53.64
Current liabilities 3946.19 5343.69 4446.97 5754.18 6736.46
Total Liabilities 10225.88 12558.7 13022.84 15793.84 18140.72
Assets
Net Block 2190.01 2568.13 3211.62 3392.97 4149.7
Capital WIP 190.49 742.14 878.31 1100.23 750.07
Investments 993.11 1183.33 1681.93 1967.48 2339.04
Loans & Advances 418.94 256.7 233.25 207.66 402.93
Other N/C Assets 65.25 33.9 114.38 144.3 90.64
Current Assets 6368.08 7774.5 6903.35 8981.2 10408.34
Total Assets 10225.88 12558.7 13022.84 15793.84 18140.72
* Other Non-current Liabilities include Net deferred Liabilities

 Cash Flows (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Profit Before Tax 1940.35 2147.84 2178.57 2342.94 1964.62
Adjustment 376.02 415.22 303.9 329.16 455.81
Working Capital Changes -1300.05 -893.68 457.02 -1219.73 -1411.6
Tax Paid -425.91 -484.2 -482.29 -529.97 -482.12
Operating Cash Flow 590.41 1185.18 2457.2 922.4 526.71
Investing Cash Flow -623.6 -1390.11 -1542.05 -990.6 -1297.36
Financing Cash Flow 34.6 514.97 -1328.99 439.69 599.4
Net Cash Flow 1.41 310.04 -413.84 371.49 -171.25

 Corporate Actions

 Ratings & Research Reports

 Company Presentations

Currently we do not have any Presentation and Concall related to this company.

 Aurobindo Pharma Stock Price Analysis and Quick Research Report

Is Aurobindo Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 526.71 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.398200617414471 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was -15.61 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 19.6550140358577 % which is a good sign for profitability.
     
  • ROE: Aurobindo Pharma have a average ROE of 14.3413957766041 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
X